Page last updated: 2024-10-25

cimetidine and Hyperlipoproteinemia Type II

cimetidine has been researched along with Hyperlipoproteinemia Type II in 1 studies

Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.
cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.

Hyperlipoproteinemia Type II: A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins).

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Calero, M1
Escobar, M1
Sampalo, A1
Senra, A1
Zamora, E1
Millán, J1

Other Studies

1 other study available for cimetidine and Hyperlipoproteinemia Type II

ArticleYear
[The hypolipemic effect of cimetidine].
    Revista clinica espanola, 1990, Volume: 187, Issue:5

    Topics: Adult; Aged; Cimetidine; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; Hyperlip

1990